BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew Sells 7,604 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 7,604 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $27.33, for a total transaction of $207,817.32. Following the completion of the transaction, the executive vice president now owns 276,315 shares of the company’s stock, valued at $7,551,688.95. This trade represents a 2.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

BioLife Solutions Price Performance

BLFS opened at $27.39 on Friday. The firm has a market cap of $1.27 billion, a PE ratio of -25.84 and a beta of 1.91. The stock has a 50-day moving average price of $24.96 and a 200-day moving average price of $23.72. BioLife Solutions, Inc. has a 1 year low of $14.50 and a 1 year high of $28.88. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78.

Institutional Investors Weigh In On BioLife Solutions

A number of institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. raised its holdings in BioLife Solutions by 4.7% in the 3rd quarter. Principal Financial Group Inc. now owns 190,715 shares of the medical equipment provider’s stock worth $4,776,000 after acquiring an additional 8,580 shares during the last quarter. Barclays PLC increased its holdings in shares of BioLife Solutions by 20.1% in the 3rd quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock worth $1,613,000 after purchasing an additional 10,803 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of BioLife Solutions by 2.2% in the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after purchasing an additional 18,473 shares during the last quarter. State Street Corp lifted its holdings in shares of BioLife Solutions by 7.3% during the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after purchasing an additional 95,788 shares in the last quarter. Finally, Stifel Financial Corp boosted its position in shares of BioLife Solutions by 5.4% during the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock valued at $325,000 after buying an additional 670 shares during the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Benchmark reissued a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a research note on Thursday. TD Cowen raised their target price on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Craig Hallum upped their price target on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. KeyCorp raised their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Finally, HC Wainwright reduced their target price on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $29.00.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.